Who are attivare's investors?

attivare's investors include MBX Capital, Ulu Ventures, Axial VC, Embark Ventures.

How much funding has attivare raised?

attivare has disclosed $5.9M raised across 1 round.

Where is attivare headquartered?

attivare is headquartered in Natick, US.

attivare

Natick, US · Founded 2020 · 4 known investors

Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.

AI & Machine Learning Biotech Medical Devices

Founders & leadership

Edward DohertyNamed on SEC filing

Jessica McDonoughNamed on SEC filing

Joaquim TriasNamed on SEC filing

Board

Zeshan MuhammediBoard director

Investors · 4

MBX CapitalClaymont · $250K – $2.5M

Ulu VenturesPalo Alto · $2M

Axial VCreportedSan Francisco · $100K – $5M

Embark VenturesreportedLos Angeles

Reported raises · per SEC filings

Form D private placements

$5.9M disclosed across 1 round · 2021

▶$5.9MraisedDec 2021 · 23 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Edward DohertyExecutive Officer
Jessica McDonoughDirector
Zeshan MuhammediDirector
Joaquim TriasExecutive Officer, Director

Offering amount: $7.8M
Amount sold: $5.9M
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Avilar Therapeutics5 shared keywordsAvilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.

Atara Biotherapeutics4 shared keywordsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.

Arvinas Holding Co. LLC4 shared keywordsArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

Veratx4 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

Aro Biotherapeutics4 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with attivare for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does attivare do?: Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.
Who are attivare's investors?: attivare's investors include MBX Capital, Ulu Ventures, Axial VC, Embark Ventures.
How much funding has attivare raised?: attivare has disclosed $5.9M raised across 1 round.
Where is attivare headquartered?: attivare is headquartered in Natick, US.